Fedratinib (INREBIC®) is a JAK2-selective inhibitor that has been developed as an oral
treatment for myelofibrosis. In August 2019, fedratinib received its first global approval in the …

Over the past decades, an increase in the incidence rate of cancer has been witnessed.
Although many efforts have been made to manage and treat this life threatening condition, it …

Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by ineffective clonal
hematopoiesis, splenomegaly, bone marrow fibrosis, and the propensity for transformation …

Janus kinase-signal transducers and activators of transcription (JAK-STAT) signaling is
critical to multiple cellular processes, including survival, differentiation, and proliferation. JAK …

Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by clonal proliferation of
differentiated myeloid cells leading to bone marrow fibrosis, cytopenias and extramedullary …

EEXPAND (phase Ib, dose-finding study) evaluated the starting dose of ruxolitinib in patients
with myelofibrosis with baseline platelet counts of 50-99× 10 9/L. The study consisted of …

The discovery of JAK2 V617F and the demonstration that BCR-ABL-negative
myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to …

Purpose: Myelofibrosis is a hematopoietic stem cell neoplasm characterized by bone
marrow reticulin fibrosis, extramedullary hematopoiesis, and frequent transformation to …

Abstract Purpose Fedratinib (SAR302503, TG101348) is an orally administered Janus
kinase (JAK) 2-selective inhibitor that is being developed for the treatment of patients with …

Abstract Purpose of Review The classic, chronic Philadelphia chromosome negative
myeloproliferative neoplasms (MPN)—essential thrombocythemia (ET), polycythemia vera …